Scientists continue studying how hemp-derived cannabinoids may support the body’s response to neuroinflammation and neurodegenerative conditions. In the review “Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration,” researchers examined how cannabinoids such as CBD, CBG, and CBC interact with microglia — the immune cells of the central nervous […]
Tag: CBG
CBG Exhibits Anti-Inflammatory, Neuroprotective, Antioxidant, and Antibacterial Effects Across Multiple Disease Models (pub. Nov 2022)
Cannabigerol (CBG) is a non-intoxicating cannabinoid found in the cannabis plant that serves as a precursor to major cannabinoids such as CBD and THC. In this 2022 scientific review, researchers examined the pharmacological properties of CBG and its synthetic derivatives, highlighting evidence that CBG interacts with multiple biological targets involved in inflammation, pain signaling, neurological […]
CBG Research Explores How Melanoma Cells Respond to Oxidative Stress and UVA Exposure (Pub. April 2026)
Researchers are continuing to study how hemp-derived cannabinoids interact with cellular stress and inflammation pathways. In the study “Metabolic responses of three distinct melanoma cell lines to UVA radiation and cannabigerol,” scientists examined how cannabigerol (CBG) affected melanoma cells exposed to UVA radiation. The research focused on oxidative stress, inflammation, and metabolic signaling pathways that […]